Company news

Kymera Therapeutics, Inc. news in 2022

Kymera Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials

December 13, 2022

Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

December 11, 2022

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

December 10, 2022

Kymera Therapeutics Provides Webcast Information for December 14 Investor Event

November 30, 2022

Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors

November 2, 2022

Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

November 2, 2022

Kymera Therapeutics to Report Third Quarter 2022 Results on November 3

October 19, 2022

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

October 12, 2022

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma

September 14, 2022

Kymera Therapeutics to Participate in Upcoming September Conferences

August 28, 2022

Kymera Announces $150 Million Private Placement Equity Financing

August 18, 2022

Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update

August 8, 2022

Kymera Therapeutics to Report Second Quarter 2022 Results on August 9

July 26, 2022

Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

July 7, 2022

Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413

June 14, 2022

Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis

May 31, 2022

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma

May 31, 2022

Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting

May 19, 2022

Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation

May 4, 2022

Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update

May 2, 2022

Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences

April 18, 2022

Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022

April 7, 2022

Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

February 23, 2022

Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences

January 24, 2022

Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors

January 17, 2022

Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company

January 9, 2022

Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

January 3, 2022

Calls in 2022

Decks in 2022